<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126177">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02037074</url>
  </required_header>
  <id_info>
    <org_study_id>EVP-6308-003</org_study_id>
    <nct_id>NCT02037074</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics</brief_title>
  <official_title>A Double-Blind, Escalating Dose Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Repeat Doses of EVP-6308 or Placebo in Subjects With Schizophrenia on a Stable Antipsychotic Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FORUM Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FORUM Pharmaceuticals Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, sequential cohort, ascending oral
      dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of EVP-6308
      administered for 14 days in subjects with schizophrenia who are on a stable anti-psychotic
      regimen.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2014</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability of EVP-6308 in subjects with schizophrenia currently receiving stable treatment with up to 2 atypical antipsychotics</measure>
    <time_frame>Baseline to Day 21 or Early Termination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Vital signs measurements, Clinical laboratory tests, Physical examination, ECG findings, Columbia-Suicide Severity Rating Scale.  Adverse events and concomitant medications will be collected from the time of signing the informed consent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of EVP-6308 in subjects with schizophrenia and the potential for EVP-6308 to affect the pharmacokinetic properties of the antipsychotic regimen</measure>
    <time_frame>Day -1 through Day 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters to be determined for EVP-6308 and EVP-6308 N-oxide metabolite include Cmax, Tmax,, AUC, and t1/2.  PK parameters to be determined for the antipsychotic include Cmax, Tmax, AUC, and CL/F.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential pharmacodynamics effects of EVP-6308</measure>
    <time_frame>Baseline to Day 21 or Early Termination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quantitative EEG, Positive and Negative Syndrome Scale, Clinician Global Impression - Severity, Barnes Akathisia Rating Scale, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, Cognitive Battery.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Experimental: EVP-6308; Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose, Capsule, Twice Daily, Day 1 through Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: EVP-6308; Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intermediate dose, Capsule, Once Daily, Day 1 through Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: EVP-6308; Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose, Capsule, Once Daily, Day 1 through Day 14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator; Arm 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, Capsule, Once Daily, Day 1 through Day 14</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: EVP-6308</intervention_name>
    <description>Arms 1, 2, 3</description>
    <arm_group_label>Experimental: EVP-6308; Arm 1</arm_group_label>
    <arm_group_label>Experimental: EVP-6308; Arm 2</arm_group_label>
    <arm_group_label>Experimental: EVP-6308; Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Arm 4</description>
    <arm_group_label>Placebo Comparator; Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ Diagnosed with schizophrenia, male or female subjects, 18 to 60 years of age

        Exclusion Criteria:

          -  Clinically significant abnormalities on physical examination, medical history,  ECG,
             vital signs, laboratory values, or unstable medical or psychiatric illness

          -  Any disorder that may interfere with drug absorption

          -  Clinically significant allergy or sensitivity to medications Positive test for human
             immunodeficiency virus (HIV) antibodies, Hepatitis B surface antigen, or Hepatitis C
             antibody

          -  Pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nathan Buerstatte</last_name>
    <phone>617-374-5784</phone>
    <email>nbuerstatte@forumpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phosphodiesterase 10 inhibitor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
